Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.

Blood - 1 Apr 2008

Dulucq Stéphanie, St-Onge Geneviève, Gagné Vincent, Ansari Marc, Sinnett Daniel, Labuda Damian, Moghrabi Albert, Krajinovic Maja

Abstract excerpt

Dihydrofolate reductase (DHFR) is the major target of methotrexate (MTX), a key component in childhood acute lymphoblastic leukemia (ALL) treatment. A total of 15 polymorphisms in DHFR promoter were analyzed, and 3 sites (C-1610G/T, C-680A, and A-317G) were identified as sufficient to define obse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Cyclin D
Share to Cyclins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Folic Acid

Share to Methotrexate

Share to RNA, Neoplasm

Share to Tetrahydrofolate Dehydrogenase

Share to Thymidylate Synthase

Source

Identifiers

PMID: 18096764
DOI: 10.1182/blood-2007-09-110593

Genes

DHFR
EFS
CCND1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18096764-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.PMID 18096764Read ↗

DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

MTHFR 677T-1298C haplotype in acute lymphoblastic leukemia: Impact on methotrexate therapy.Semantic proximity Read ↗

Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.Semantic proximity Read ↗

Significance of 5,10-methylenetetrahydrofolate reductase gene variants in acute lymphoblastic leukemia in Indian population: an experimental, computational and meta-analysis.Semantic proximity Read ↗

Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.Semantic proximity Read ↗

Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.Semantic proximity Read ↗

Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapySemantic proximity Read ↗

Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

The methylenetetrahydrofolate reductase 677T-1298C haplotype is a risk factor for acute lymphoblastic leukemia in children.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase gene polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis based on 28 case-control studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.